An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia.
An open-label trial of the selective cyclo-oxygenase-2 inhibitor rofecoxib in inflammatory bowel disease-associated peripheral arthritis and arthralgia